How Is Quest Diagnostics' Stock Performance Compared to Other Diagnostics & Research Stocks?
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
Company Overview: Quest Diagnostics, valued at $17.1 billion, is a leading provider of diagnostic testing and services in the U.S. and internationally, with a focus on growth through strategic partnerships and enhanced service offerings.
Stock Performance: Despite a recent decline of 1.2% over three months, DGX stock has increased by 10.4% year-to-date, driven by strong Q3 results that exceeded expectations, prompting an optimistic revenue outlook for the year ahead.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 304.45 USD with a low forecast of 270.00 USD and a high forecast of 325.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 269.970
Low
270.00
Averages
304.45
High
325.00
Current: 269.970
Low
270.00
Averages
304.45
High
325.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
